drugset / Trial / NCT02376036

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036

Phase 1 Completed 73 enrolled MacroGenics
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.

Timeline

Start
2015-02
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Havrix Vaccine Intramuscular
Subject MGD010 Unknown Intravenous

Indications

No indication recorded.